Emerging treatments for ovarian cancer. - Wikidata - awgldk - TriplyDB

Emerging treatments for ovarian cancer.

Emerging treatments for ovarian cancer.

http://www.wikidata.org/entity/Q35581174

about

Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.

P2860

Q38333986-695FE66A-AA22-4AAC-AD0D-5F0EB06C2466

P2860

Emerging treatments for ovarian cancer.

http://www.wikidata.org/entity/Q35581174

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Emerging treatments for ovarian cancer.

@ast

Emerging treatments for ovarian cancer.

@en

type

label

Emerging treatments for ovarian cancer.

@ast

Emerging treatments for ovarian cancer.

@en

prefLabel

Emerging treatments for ovarian cancer.

@ast

Emerging treatments for ovarian cancer.

@en

P1433

Q35581174-D24D5077-127C-4BB9-8897-6C2931087535

P1476

Q35581174-D1F62D4C-9E2C-4A27-ABA9-6FB6E4BD00AA

P2093

Q35581174-E8F875CD-4165-4251-B14A-10807D19DB75

P2860

Q35581174-0AB3D912-F39B-40C0-A29B-70E4CA186D47

Q35581174-0C253E1D-A4DC-4CBF-BB01-AA41EA0D5BBE

Q35581174-17541092-76C0-4AED-B4D8-51020458DF36

Q35581174-18191B1B-6B31-4CE1-91A5-FB5B153443A9

Q35581174-1A93616E-9EC4-4D4A-9D02-88192454F456

Q35581174-22D39F86-BB31-4EC3-B996-CCCFC97CB6DF

Q35581174-39B4B117-3BF4-4A2D-8779-E1E11D184853

Q35581174-3DEA7F74-5857-44A3-B2BF-FFD9EBB333A9

Q35581174-45B6E141-BD18-402E-A4B6-274C94B0139C

Q35581174-483B3141-A995-4F05-8042-D031065E924D

P304

Q35581174-25A051D3-A86F-4659-9E34-55170048DB19

P31

Q35581174-DE35E55B-4C9E-4802-A372-2826AD913CCB

P356

Q35581174-6ED26D9B-FE61-4B1F-80BF-D500D4BFCCFD

P407

Q35581174-DB8DF772-6446-4E64-93EF-04AA4AD56076

P433

Q35581174-4E34D0BD-FC08-47EB-A24E-3B54EBEFEBCA

P478

Q35581174-A30BCF2D-29F1-44DC-9A5E-55395D469956

P50

Q35581174-3B5549F7-D510-4E5F-849F-0933F6083EFE

P577

Q35581174-B45BB403-DB9A-436D-94EE-E1BC65157FC2

P698

Q35581174-A644DCBA-FBEC-40F8-BBF8-F361D30391DF

P921

Q35581174-57C6E06B-B355-4DA3-B092-B3227E3A17C1

P356

14728214.8.1.203

P1433

Expert Opinion on Emerging Drugs

P1476

Emerging treatments for ovarian cancer.

@en

P2093

M Janice Lu

http://www.w3.org/2001/XMLSchema#string

P2860

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews

Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.

Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer.

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Phase I clinical trial of a new anthracycline: 4'-o-tetrahydropyranyl adriamycin.

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.

A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.

The epidemiology of ovarian cancer.

P304

203-216

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728214.8.1.203

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14610922

http://www.w3.org/2001/XMLSchema#string

P921